Anavex Life Sciences Corp.
AVXL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $10 | $10 | $10 | $12 |
| G&A Expenses | $5 | $3 | $3 | $3 |
| SG&A Expenses | $5 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14 | $13 | $14 | $14 |
| Operating Income | -$14 | -$13 | -$14 | -$14 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $3 |
| Pre-Tax Income | -$13 | -$11 | -$13 | -$12 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | -$13 | -$11 | -$12 | -$12 |
| % Margin | – | – | – | – |
| EPS | -0.16 | -0.13 | -0.14 | -0.14 |
| % Growth | -23.1% | 7.1% | 0% | – |
| EPS Diluted | -0.16 | -0.13 | -0.14 | -0.14 |
| Weighted Avg Shares Out | 85 | 85 | 85 | 84 |
| Weighted Avg Shares Out Dil | 85 | 85 | 85 | 84 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $12 | $1 | -$23 |
| EBITDA | -$13 | $1 | -$11 | -$34 |
| % Margin | – | – | – | – |